US FDA Signals Increased Enforcement Activity against Prescription Drug Advertising and Promotion
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is increasingly issuing letters to companies alleging violations in promotional material for prescription drugs, say Gerald Masoudi and Stefanie Doebler.
You may also be interested in...
Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.
Teva’s Austedo Fails In Tourette’s Syndrome
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: